anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Show Traction

Slide function collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 11,828
Current window 6,811-6,840
Pages 395
Rows per page 30
Slide function: Show Tractionclear collectionreset all
18 30 60

Slide function

6,811-6,840 of 11,828

filter-aware
26
The chart shows a breakdown of AUM by service type (Investment Agency, Managed Trust, 401(k)/Retirement, Directed Trust, Custody) over five quarters.First Western Financial | Investor Presentation Deck | 50 slides · First Western Financial
Pitch deck Investor relations 1 hit
08
The slide uses a timeline to establish market maturity and investor confidence.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
11
The slide uses a document-style callout for key takeaways and a vertical icon-list for clinical data points.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
12
The slide uses a process-flow layout to show the trial design and its validation through publications and follow-up trials.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
14
Waterfall plot and spider plot showing patient-level clinical outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
16
Kaplan-Meier survival curve showing superior performance of VIRO-15 compared to historical 4th line treatment data.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
20
Includes specific patient case reports (Pt #21A-06 and Pt #21A-04) as evidence of efficacy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide highlights a strategic partnership, funding, and commercial rights split between US and Greater China markets.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
The slide compares pre- and post-treatment biopsies for three patients (15A-16, 15A-18, 15A-23) using both visual microscopy and quantitative infiltration histograms.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
The slide uses a combination of a bar chart (ELISPOT data) and a line chart (SLD over time) to show clinical efficacy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
09
The slide highlights the clinical validation of HeartBeam's VECG technology.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
06
Includes a background map graphic and specific footnotes regarding non-GAAP measures.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
14
The slide uses two bar charts to demonstrate the correlation between headcount growth and revenue efficiency.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
The slide uses a two-part structure: a chronological list of service expansions and a logo-grid of acquisitions with dates.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
The slide uses a stacked table visual to represent multiple #1 rankings across different sectors.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
22
The slide uses competitive benchmarking to establish authority in the restructuring market.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Competition1 hit
24
The slide uses a split-layout to combine qualitative value propositions with a quantitative ranking table.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
26
The slide highlights financial resilience and scalability through market cycles.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Financials1 hit
11
The chart illustrates the mechanism of action and efficacy of NXC-201 (formerly HBI0101) in treating AL Amyloidosis.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
27
The slide uses a side-by-side comparison of two disease indications, showing clinical results, relevant competitor benchmarks, and market size.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
28
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
35
Includes a process diagram illustrating the mechanism of action of IMX-110 in turning cold tumors hot.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
36
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
38
Includes waterfall charts and longitudinal patient response plots. Source note provided at bottom.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
40
The slide uses a combination of a conceptual chart and a data table to highlight efficacy and safety in a small sample size (n=4).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit